Precision Molecular Announces Investment by Alzheimer’s Drug Discovery Foundation to Support Advancement of More Effective Agents for Imaging Neuroinflammation
GERMANTOWN, Maryland–(BUSINESS WIRE)–Precision Molecular, Inc. (PMI), a clinical-stage company with the mission to develop imaging biomarkers and theranostics, today announced…